TABLE 2.

Characteristics of patients with oligoprogression or oligometastasis who received ICI treatment (n = 38)

	Received LAT n ＝ 10	Did not receive LAT n ＝ 28	P‐value
Age, median (range)	63.5 (53‐78)	70.0 (48‐87)
Sex, female/male	1/9	4/24	1.00
ECOG P performance status, 0/1/2	3/7/0	14/13/1	.475
Driver mutation
Positive (%)	1 (10%)	5 (18%)	1.00
Histology
Ad/Sq/other	2/4/4	13/11/4	.197
Smoking history
Yes/No	9/1	26/2	1.00
Stage
Postoperative recurrence/III/IV	3/1/6	3/5/20	.521
ICI treatment
Nivolumab/Pembrolizumab	8/2	17/11	.406
ICI line
1/2/3 or later	1/7/2	8/13/7	.499

Abbreviations: Ad, adenocarcinoma; ECOG, Eastern Cooperative Group; ICI, immune checkpoint inhibitor; LAT, local ablative therapy; Non‐oligo, non‐oligoprogression; Oligo, oligoprogression; PFS, progression‐free survival; Sq, squamous cell carcinoma.

Major driver gene alterations were not evaluated in 5 patients because of the presence of pure squamous cell carcinoma histology.